Interview with Dr. Francisco Sanchez-Madrid regarding Pivotal Advance: CD69 targeting differentially affects the course of collagen-induced arthritis. Interview by Helene F. Rosenberg.
Sanchez-Madrid
Francisco
F
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D001169:Arthritis, Experimental / Q000188:drug therapy / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D004195:Disease Models, Animal; D007074:Immunoglobulin G / Q000276:immunology* / Q000627:therapeutic use; D037181:Lectins, C-Type; D008212:Lymphocyte Depletion / Q000379:methods; D051379:Mice; D013601:T-Lymphocytes / Q000276:immunology; D000099192:CD69 Antigens
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D007074:Immunoglobulin G; D037181:Lectins, C-Type; D000099192:CD69 Antigens